home / stock / govxw / govxw news

GOVXW News and Press, GeoVax Labs Inc. Warrants From 04/19/22

Stock Information
Company Name: GeoVax Labs Inc. Warrants
Stock Symbol: GOVXW
Market: NASDAQ
Website: geovax.com
Menu
GOVXW GOVXW Quote GOVXW Short GOVXW News GOVXW Articles GOVXW Message Board
Get GOVXW Alerts

News, Short Squeeze, Breakout and More Instantly...
GOVXW - GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update

Conference call to be held Wednesday, April 27, at 4:30 p.m. Eastern Time ATLANTA, GA, April 19, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against infectious diseas...
GOVXW - CORRECTION - Aura FAT Projects Acquisition Corp. Announces Closing of Initial Public Offering and Exercise of Full Over-Allotment Option

Singapore, April 18, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire--In a release issued under the same headline on Monday, April 18 th at 1:55 ET by GeoVax, Inc., please note that the release was distributed under the incorrect source and should have been sourced to Aura FAT Projects Acquis...

GOVXW - GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress

Company’s COVID-19 Vaccine Candidate GEO-CM04S1 Continues to Advance in COVID-19 Phase 2 Clinical Trials While the Experimental Universal Vaccine Candidate GEO-CM02 Demonstrated Single-Dose, 100% Protection in Lethal Animal Challenge Model Atlanta, GA, April 12, 2022 (G...

GOVXW - GeoVax Announces Issuance of Cancer Vaccine Patent

IND-Enabling Studies Underway for MVA-VLP-MUC1 Vaccine Candidate Atlanta, GA, March 22, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing human immunotherapies and vaccines against infectious diseases and ...
GOVXW - GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022

Presentation to Focus on GEO-CM02 Being Developed as a Universal Vaccine to Address Evolving SARS-CoV-2 Variants ATLANTA, GA, March 21, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in deve...

GOVXW - GeoVax to Participate in Maxim Group's 2022 Virtual Growth Conference

Chairman & CEO David Dodd to Present Corporate Update CSO Mark Newman, PhD to Participate in Fireside Chat with Maxim Analyst Jason McCarthy, PhD ATLANTA, GA , March 16, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc . (...

GOVXW - GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials

Comparative Trial Against Pfizer/BioNTech Vaccine Among Immunocompromised Patients Booster to Pfizer/BioNTech or Moderna Vaccines Among Healthy Patients ATLANTA, GA, March 14, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX)...
GOVXW - Data Published in a Lancet Journal on COH04S1, a City of Hope-Developed COVID-19 Vaccine, Shows it Produced Robust Antibodies and T cells Against SARS-CoV-2

The investigational vaccine is now being used in Phase 2 trials for immunocompromised patients and as a booster for healthy adult volunteers LOS ANGELES and ATLANTA, March 10, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – A COVID-19 investigational vaccine, developed by Cit...

GOVXW - GeoVax Reports 2021 Year-End Financial Results and Provides Corporate Update

Advancing Phase 2 Clinical Trials for COVID-19 and Immuno-Oncology ATLANTA, GA, March 09, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against infectious diseases and ...

GOVXW - GeoVax Announces Key Staff Appointments

Operational Resources Strengthened in Support of Ongoing Phase 2 Clinical Trials for COVID-19 and Advanced Head & Neck Cancer ATLANTA, GA, March 07, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing ...
Previous 10 Next 10